secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001493152-26-014951
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics director Allan Camaisa to step down at 2026 annual meeting; Board reduced to 5
--------------------------------------------------------------------------------

- Director Allan J. Camaisa will not stand for re-election; term expires at 2026 annual meeting; no disagreement with company.
- Board reduced from six to five directors effective at the 2026 annual meeting.
- Scott Leftwich appointed to Audit Committee effective April 1, 2026.
- Camaisa's departure is not due to any disagreement with company operations or policies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226014951/0001493152-26-014951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226014951/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-014951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer